Methods and compositions for treating erectile dysfunction

Abstract

Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone and/or the fast-acting erectile dysfunction drug deposits on lung tissue and then enter the patient's circulatory system.

1 .- 18 . (canceled)  
     
     
         19 . A kit for the treatment of erectile dysfunction in a man, comprising: 
 a hand-held device for the aerosolized delivery of a formulation;    a container of an aerosolizable formulation comprising a phosphodiesterase (PDE) inhibitor.    
     
     
         20 . The kit of  claim 19 , further comprising: 
 a plurality of containers of aerosolizable formulation of a phosphodiesterase (PDE) inhibitor.    
     
     
         21 . The kit of  claim 19 , further comprising: 
 instructions for administering the formulation to treat erectile dysfunction.    
     
     
         22 . The kit of  claim 20 , wherein each of the containers of a phosphodiesterase (PDE) inhibitor comprises 25 mg of aerosolizable phosphodiesterase (PDE) inhibitor.  
     
     
         23 . The kit of  claim 20 , wherein each of the containers of a phosphodiesterase (PDE) inhibitor comprises 25 mg to 100 mg of aerosolizable phosphodiesterase (PDE) inhibitor.  
     
     
         24 . The kit of  claim 19 , comprising from 1 to 100 containers of aerosolizable formulation of a phosphodiesterase (PDE) inhibitor.  
     
     
         25 . The kit of  claim 19 , comprising from 1 to 30 containers of aerosolizable formulation of a phosphodiesterase (PDE) inhibitor.  
     
     
         26 . The kit of  claim 19 , wherein the formulation is a liquid formulation.  
     
     
         27 . The kit of  claim 19 , wherein the formulation is a dry powder.  
     
     
         28 . The kit of  claim 19 , wherein the formulation comprises a pressurized propellant.  
     
     
         29 . A kit, comprising: 
 a plurality of containers of a formulation for pulmonary delivery, the formulation comprising a phosphodiesterase (PDE) inhibitor; and    instructions for administering the formulation to treat erectile dysfunction.    
     
     
         30 . The kit of  claim 29 , wherein the phosphodiesterase (PDE) inhibitor is chosen from Viagra and Clalis.  
     
     
         31 . The kit of  claim 29 , wherein the formulation is a liquid formulation.  
     
     
         32 . The kit of  claim 29 , wherein the formulation is a dry powder.  
     
     
         33 . The kit of  claim 29 , wherein the formulation comprises a pressurized propellant.  
     
     
         34 . A method of treating erectile dysfunction, comprising: 
 aerosolizing a formulation comprising a phosphodiesterase (PDE) inhibitor;    inhaling the aerosolized formulation comprised of a phosphodiesterase (PDE) inhibitor into lungs of a patient to be treated for erectile dysfunction;    allowing particles comprised of a phosphodiesterase (PDE) inhibitor to deposit on lungs of the patient and enter the patient's circulatory system.    
     
     
         35 . The method of  claim 34 , wherein the formulation is a liquid formulation.  
     
     
         36 . The method of  claim 34 , wherein the formulation is a dry powder.  
     
     
         37 . The method of  claim 34 , wherein the formulation comprises a pressurized propellant.  
     
     
         38 . A kit for the treatment of erectile dysfunction in a man, comprising: 
 a hand-held device for the aerosolized delivery of a formulation;    a container of an aerosolizable formulation comprising a compound chosen from a dopamine receptor agonist, a melanocortin receptor agonist, a growth hormone-releasing peptide receptor agonist, and an alpha-adrenoceptor antagonist.    
     
     
         39 . The kit of  claim 38 , further comprising: 
 a plurality of containers of aerosolizable formulation of a compound chosen from a dopamine receptor agonist, a melanocortin receptor agonist, a growth hormone-releasing peptide receptor agonist, and an alpha-adrenoceptor antagonist.    
     
     
         40 . The kit of  claim 38 , further comprising: 
 instructions for administering the formulation to treat erectile dysfunction.    
     
     
         41 . A method of treating erectile dysfunction, comprising: 
 aerosolizing a formulation comprising a drug which is a compound chosen from a dopamine receptor agonist, a melanocortin receptor agonist, a growth hormone-releasing peptide receptor agonist, and an alpha-adrenoceptor antagonist;    inhaling the aerosolized formulation comprised of the drug into lungs of a patient to be treated for erectile dysfunction;    allowing particles comprised of the drug to deposit on lungs of the patient and enter the patient's circulatory system.    
     
     
         42 . The method of  claim 41 , wherein the formulation is a liquid formulation.  
     
     
         43 . The method of  claim 41 , wherein the formulation is a dry powder.